ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1472

Incidence and Mortality in a Population-Based Cohort of Patients with Juvenile Arthritis 1960-2013

Megan L. Krause1, Cynthia S. Crowson2, C. John Michet III1, Theresa Wampler Muskardin3, Thomas Mason II1 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Juvenile arthritis and morbidity and mortality

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:
Information regarding incidence, prevalence, and mortality in juvenile
rheumatoid arthritis is scarce, particularly since the advent of recent
classification criteria for juvenile inflammatory arthritis (JIA). Estimates
are based on varying populations, classification criteria, follow-up durations,
and disease validation methodology.   

Methods: Incident
cases of juvenile arthritis were identified between January 1, 1994 and
December 31, 2013 in a geographically well-defined population using individual
medical record review for case validation. Cases meeting ACR criteria for
juvenile rheumatoid arthritis (JRA) and ILAR criteria for juvenile idiopathic
arthritis (JIA) were included. Individuals who met criteria for JRA were
combined with a prior cohort of incident cases from 1960-1993.1 Incidence
and prevalence rates with 95% confidence intervals (CI) were sex- and
age-adjusted to the 2010 U.S. white population. The standardized mortality
ratio (SMR) with 95% CI was calculated with expected deaths based on age, sex
and calendar year specific life tables for the U.S. population and displayed
using Kaplan-Meier methods. 

Results: Fifty-nine
incident cases met JRA criteria in 1994-2013. Disease subtypes included 48
(81%) with pauciarticular disease, and 9 (15%) with polyarticular and 2 (3%)
with systemic disease. These JRA patients were combined with the additional 59
patients from the previously identified 1960-1993 cohort for a total of 118
patients. There were no differences in the subtypes of JRA, age at diagnosis,
sex, or time from symptoms to diagnosis comparing the 2 cohorts. The incidence
of JRA in 1994-2013 was 9.5 per 100,000 (95% CI 7.1, 12.0).  Prevalence of JRA
on 1/1/2010 was 54.4 per 100,000 (95% CI 28.5, 80.2). There was no significant
change in the incidence of JRA over the entire time period.      

Utilizing JIA criteria, 71 incident cases were
identified in 1994-2013.  Incidence was 10.3 per 100,000 (95% CI 7.9, 12.7).
Prevalence on 1/1/2010 was 57.6 per 100,000 (95% CI 31.0, 84.5). Oligoarthritis
was the most common subtype accounting for 63%. Joint erosions were noted in
17% and eye involvement in 7%.

A total of 4 deaths occurred during 2180.7
person-years of follow-up in patients with JRA. No deaths have occurred in
children with incident JRA in 1994-2013. None of the deaths were directly
related to juvenile arthritis. The SMR was 1.50 (95% CI 0.41-3.83); the survival
curve is shown in figure 1.       

Conclusion:   The
incidence of JRA did not change significantly between 1960-2013. Incidence is
higher when using the more inclusive criteria of JIA as compared to JRA.  When
specifically evaluating the more homogeneous group of patients who met ACR JRA
criteria, there was no demonstrated increase in mortality compared to the
general population.

1Peterson
LS, et al. Arthritis Rheum 1996;39(8):1385-90.

 


Disclosure: M. L. Krause, None; C. S. Crowson, None; C. J. Michet III, None; T. Wampler Muskardin, None; T. Mason II, None; E. L. Matteson, Novartis/Sanofi/Centocor-Jansen/Celgene/Amgen/Roche/Genentech/Mesoblast/Pfizer, 2.

To cite this abstract in AMA style:

Krause ML, Crowson CS, Michet CJ III, Wampler Muskardin T, Mason T II, Matteson EL. Incidence and Mortality in a Population-Based Cohort of Patients with Juvenile Arthritis 1960-2013 [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/incidence-and-mortality-in-a-population-based-cohort-of-patients-with-juvenile-arthritis-1960-2013/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-mortality-in-a-population-based-cohort-of-patients-with-juvenile-arthritis-1960-2013/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology